Cisplatin‐conjugated gold nanoparticles as a theranostic agent for head and neck cancer
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: The purpose of this study was to develop a nanoplatform, which simultaneously acts as radiosensitizer, drug carrier, and tumor imaging agent for head and neck cancer. Methods: We synthesized 20 nm gold nanoparticles, coated with glucose and cisplatin (CG‐GNPs). Their penetration into tumor cells and their cellular toxicity were evaluated in vitro. In vivo experiments were conducted to evaluate their impact on tumor growth and their imaging capabilities. Results: The CG‐GNPs showed efficient penetration into tumor cells and similar cellular toxicity as cisplatin alone. Combined with radiation, CG‐GNPs led to greater tumor reduction than that of radiation alone and radiation with free cisplatin. The CG‐GNPs also demonstrated efficient tumor imaging capabilities. Conclusion: Our CG‐GNPs have a great potential to increase antitumor effect, overcome resistance to chemotherapeutics and radiation, and allow imaging‐guided therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research
Ivashkevich, A., Redon, C. E., Nakamura, A. J., Martin, R. F., & Martin, O. A. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.025 · Cited by 462
Song, G., Chen, Y., Liang, C., Yi, X., Liu, J., Sun, X., Shen, S., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201602111 · Cited by 394
Cited by
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy
Chen, Y., Yang, J., Fu, S., & Wu, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272902 · Cited by 319
Bilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52
“Furthermore, it was found to be more effective as a radiosensitizer than free cisplatin due to increased accumulation within cancer cells.75 Cisplatin has also been conjugated to gold NPs for tumor sensitization of head and neck cancers, as well as glioblastoma.76,77 This is doubly beneficial as the gold NPs in themse…”
BackgroundInsights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment
Viegas, C., Pereira, D. S. M., & Fonte, P. (2022) · Materials · doi:10.3390/ma15062086 · Cited by 21
“nosis and image-guided therapy, making it a promising theragnostic agent [163].”
BackgroundEvaluation of efficacy of tumor-specific nanoliposomal radiosensitizer in radiotherapy
Karabuga, M., Erdogan, S., Filikci, K., Hazıroglu, R., Tuncel, M., & Cengiz, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104586 · Cited by 6
Metadata
- Authors
- Davidi, E. S., Dreifuss, T., Motiei, M., Shai, E., Bragilovski, D., Lubimov, L., Kindler, M. J. J., Popovtzer, A., Don, J., & Popovtzer, R.
- Venue
- Head & Neck
- Publisher
- Wiley
- Published
- 2017-11-11
- Volume
- 40
- Issue
- 1
- Pages
- 70-78
- ISSN
- 1043-3074 (ISSN-L)
- 1097-0347
- OpenAlex
- W2767710270
- Cited by
- 91
- References
- 3
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.